Dr. Hildebrand founded Pure Transplant Solutions in 2003. He is the Presbyterian Health Foundation Endowed Professor and the Robert Glenn Rapp Foundation Presidential Professor in the Department of Microbiology and Immunology at The University of Oklahoma Health Sciences Center. He has been a CLIA Accredited Clinical HLA Laboratory Director and an American Board for Histocompatibility and Immunogenetics Diplomate (ASHI) since 1998. Dr. Hildebrand has been awarded over $40M in grants from Oklahoma State and Federal government agencies as well as private corporations. He has authored over 120 publications, reviews, and book chapters in peer-reviewed industry works and popular science journals. He was Associate Editor of the Journal of Immunology from 2006-2010. He has served on editorial, advisory, and national review panel boards for the NIH, Center for HIV/AIDS Vaccine Immunology (CHAVI), American Society for Hematology, NIAID and the National Marrow Donor Program. He holds a total of 77 patents in fields related to the discovery and use of the HLA molecule technology he has developed and has appeared on numerous radio and television news programs and in public service announcements highlighting his research.

Dr. Buchli has served as the Director of Research in the PTS lab since 2001. His work is essential to the completion of ongoing research to develop new methodologies and technologies for developing novel soluble HLA proteins for one of the foremost biomedical companies in the country. Dr. Buchli received his PhD in Biochemistry from the University of Basel and served as a Postdoctoral Researcher at UC Davis until 2001 before accepting a Research Assistant Professor position at the University of Oklahoma, Health Science Center. He is the recipient of the Albert M. Kligman Award in Dermatology and The Journal Record’s On the Brink Innovator Award. Dr. Buchli is co-inventor on multiple International and United States patents and authored over publications.